Obesity combined with Aβ infusion significantly increased IBA-1 immunoreactivity relative to vehicle-treated control mice (F = 2.96, p = 0.05; Fig. 5b) and increased GFAP immunoreactivity compared to all other groups (F = 5.13, p = 0.004; Fig. 5c). Here, GFAP is linked to obesity disorder.